Cargando…

A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis

Carbapenem-resistant Acinetobacter baumannii (CRAB), an important nosocomial pathogen, occurs particularly in the intensive care unit (ICU). Thus, the aim of this study was to compare the efficacy and safety of documented treatment with colistin monotherapy versus colistin plus meropenem in critical...

Descripción completa

Detalles Bibliográficos
Autores principales: Katip, Wasan, Uitrakul, Suriyon, Oberdorfer, Peninnah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599589/
https://www.ncbi.nlm.nih.gov/pubmed/32998187
http://dx.doi.org/10.3390/antibiotics9100647
_version_ 1783602913017331712
author Katip, Wasan
Uitrakul, Suriyon
Oberdorfer, Peninnah
author_facet Katip, Wasan
Uitrakul, Suriyon
Oberdorfer, Peninnah
author_sort Katip, Wasan
collection PubMed
description Carbapenem-resistant Acinetobacter baumannii (CRAB), an important nosocomial pathogen, occurs particularly in the intensive care unit (ICU). Thus, the aim of this study was to compare the efficacy and safety of documented treatment with colistin monotherapy versus colistin plus meropenem in critically ill patients with CRAB infections at Chiang Mai University Hospital (CMUH). We conducted a retrospective cohort study of critically ill patients with CRAB infections in an ICU from 2015 to 2017, who received colistin monotherapy versus colistin plus meropenem. After propensity score matching, an adjusted odds ratio (aOR) of a 30-day mortality rate in patients who received colistin plus meropenem was 0.43 compared to those who received colistin monotherapy (95% CI, 0.23–0.82, p = 0.01). aORs of clinical response and microbiological response were also higher in patients who received colistin plus meropenem (1.81, 95% CI 1.01–3.26, p = 0.048 and 2.08, 95% CI 1.11–3.91, p = 0.023, respectively). There was no significant difference in nephrotoxicity (aOR, 0.76, 95% CI, 0.43–1.36, p = 0.363) between colistin monotherapy and colistin plus meropenem. In conclusion, the addition of meropenem to colistin caused a reduction in 30-day mortality, higher clinical and microbiological responses, and did not increase nephrotoxicity compared to colistin monotherapy. Furthermore, 30-day mortality was significantly related with age, receiving vasopressor, having malignancy, and the APACHE II score.
format Online
Article
Text
id pubmed-7599589
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75995892020-11-01 A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis Katip, Wasan Uitrakul, Suriyon Oberdorfer, Peninnah Antibiotics (Basel) Article Carbapenem-resistant Acinetobacter baumannii (CRAB), an important nosocomial pathogen, occurs particularly in the intensive care unit (ICU). Thus, the aim of this study was to compare the efficacy and safety of documented treatment with colistin monotherapy versus colistin plus meropenem in critically ill patients with CRAB infections at Chiang Mai University Hospital (CMUH). We conducted a retrospective cohort study of critically ill patients with CRAB infections in an ICU from 2015 to 2017, who received colistin monotherapy versus colistin plus meropenem. After propensity score matching, an adjusted odds ratio (aOR) of a 30-day mortality rate in patients who received colistin plus meropenem was 0.43 compared to those who received colistin monotherapy (95% CI, 0.23–0.82, p = 0.01). aORs of clinical response and microbiological response were also higher in patients who received colistin plus meropenem (1.81, 95% CI 1.01–3.26, p = 0.048 and 2.08, 95% CI 1.11–3.91, p = 0.023, respectively). There was no significant difference in nephrotoxicity (aOR, 0.76, 95% CI, 0.43–1.36, p = 0.363) between colistin monotherapy and colistin plus meropenem. In conclusion, the addition of meropenem to colistin caused a reduction in 30-day mortality, higher clinical and microbiological responses, and did not increase nephrotoxicity compared to colistin monotherapy. Furthermore, 30-day mortality was significantly related with age, receiving vasopressor, having malignancy, and the APACHE II score. MDPI 2020-09-28 /pmc/articles/PMC7599589/ /pubmed/32998187 http://dx.doi.org/10.3390/antibiotics9100647 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Katip, Wasan
Uitrakul, Suriyon
Oberdorfer, Peninnah
A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis
title A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis
title_full A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis
title_fullStr A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis
title_full_unstemmed A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis
title_short A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: A Propensity Score-Matched Analysis
title_sort comparison of colistin versus colistin plus meropenem for the treatment of carbapenem-resistant acinetobacter baumannii in critically ill patients: a propensity score-matched analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599589/
https://www.ncbi.nlm.nih.gov/pubmed/32998187
http://dx.doi.org/10.3390/antibiotics9100647
work_keys_str_mv AT katipwasan acomparisonofcolistinversuscolistinplusmeropenemforthetreatmentofcarbapenemresistantacinetobacterbaumanniiincriticallyillpatientsapropensityscorematchedanalysis
AT uitrakulsuriyon acomparisonofcolistinversuscolistinplusmeropenemforthetreatmentofcarbapenemresistantacinetobacterbaumanniiincriticallyillpatientsapropensityscorematchedanalysis
AT oberdorferpeninnah acomparisonofcolistinversuscolistinplusmeropenemforthetreatmentofcarbapenemresistantacinetobacterbaumanniiincriticallyillpatientsapropensityscorematchedanalysis
AT katipwasan comparisonofcolistinversuscolistinplusmeropenemforthetreatmentofcarbapenemresistantacinetobacterbaumanniiincriticallyillpatientsapropensityscorematchedanalysis
AT uitrakulsuriyon comparisonofcolistinversuscolistinplusmeropenemforthetreatmentofcarbapenemresistantacinetobacterbaumanniiincriticallyillpatientsapropensityscorematchedanalysis
AT oberdorferpeninnah comparisonofcolistinversuscolistinplusmeropenemforthetreatmentofcarbapenemresistantacinetobacterbaumanniiincriticallyillpatientsapropensityscorematchedanalysis